Blockbuster hepatitis C medicine Harvoni propelled Gilead Sciences Inc.'s second-quarter profit up 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Its shares jumped in after-hours trading. … Click to Continue »